All In Biotech

Drug Trial Radar · NCT03099603

A Study of HTD1801 in Healthy Subjects

A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Mar 24, 2017

Primary completion

Jul 11, 2017

Study completion Oct 3, 2017

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.

Conditions

  • Primary Sclerosing Cholangitis

Interventions

  • HTD1801Drug

    A small molecular compound for the treatment of primary sclerosing cholangitis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single doseTime frame: up to Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Limited

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.